Paper Details

  1. Home
  2. Paper Details

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

Author: HibiToshifumi, IidaMitsuo, ItoHiroaki, MatsumotoTakayuki, SasakiHidetaka, SuzukiYasuo, TakanoYuichi, YoshidaToyomitsu

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

A higher dose of the pH-dependent release formulation of mesalamine was more effective for inducing remission in patients with mild-to-moderate active ulcerative colitis. The pH-dependent release formulation was also preferable for patients with proctitis-type UC.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC. METHODS: In a multicenter, double-blind, randomized study, 229 patients with mi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972638/

データ提供：米国国立医学図書館（NLM）

Mesalamine for Ulcerative Colitis: A Relief from the Desert Heat

Ulcerative colitis, a chronic inflammatory bowel disease, can cause significant discomfort and impact daily life. It's like being caught in a desert heat wave, with relentless inflammation and pain. This study compared the efficacy and safety of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis. They found that a higher dose of the pH-dependent release formulation was more effective than the time-dependent release formulation in inducing remission. This discovery is like finding a more potent and effective way to combat the desert heat, providing longer-lasting relief.

pH-Dependent Mesalamine: A Targeted Approach

The study found that the higher dose of the pH-dependent release formulation was more effective in inducing remission in patients with ulcerative colitis. This suggests that this formulation, which releases mesalamine in the colon where it is needed, is a promising treatment option. It's like finding a way to direct the cooling breeze to the specific areas that need it most, offering targeted relief from the desert heat.

Ulcerative Colitis: A Journey of Management

Ulcerative colitis is a chronic condition, and finding the right treatment plan is crucial for managing symptoms and improving quality of life. It's like navigating a desert landscape, finding ways to adapt to the challenges and minimize the impact. Working with a healthcare professional to find the best treatment approach can help patients manage their condition and find a path to a more comfortable and fulfilling life.

Dr. Camel's Conclusion

This study provides valuable insights into the treatment of ulcerative colitis, highlighting the importance of choosing the right mesalamine formulation for each individual. It's like selecting the right camel to navigate the desert of inflammation, ensuring a smoother and more comfortable journey.

Date :
  1. Date Completed 2010-12-16
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

20049950

DOI: Digital Object Identifier

PMC2972638

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.